Clinical Scorecard: Development of a Pediatric Diagnostic Score for Familial Hypercholesterolemia (FH-PeDS)

At a Glance

Key Highlights

• Existing FH diagnostic criteria underperform in pediatric populations, identifying less than half of genetically confirmed cases.
• FH-PeDS, a novel semi-quantitative pediatric diagnostic score, outperforms the Dutch Lipid Clinics Network (DLCN) criteria in accuracy.
• ML-FH-PeDS, a machine learning model, demonstrates superior predictive power and can guide genetic testing decisions.

Guideline-Based Recommendations

Diagnosis

• Use FH-PeDS or ML-FH-PeDS tools to improve early detection of FH in children.
• Consider genetic testing for children identified as high risk by these diagnostic tools, especially when family history is incomplete.
• Recognize limitations of adult-based FH diagnostic criteria when applied to pediatric patients.

Management

• Initiate early lipid-lowering interventions upon diagnosis to reduce long-term cardiovascular risk.
• Use clinical diagnostic tools to prioritize children for genetic testing in resource-limited settings.

Monitoring & Follow-up

• Regularly monitor lipid profiles in children diagnosed or suspected of having FH to guide treatment efficacy.
• Follow-up assessments should consider cardiovascular risk progression from childhood.

Risks

• Underdiagnosis of FH in childhood leads to missed opportunities for early intervention and increased risk of premature ASCVD.
• Reliance solely on cholesterol levels or adult criteria may result in misclassification.

Patient & Prescribing Data

Pediatric patients with hypercholesterolemia, including those with genetically confirmed FH

Early identification via FH-PeDS or ML-FH-PeDS enables timely lipid-lowering therapy initiation, potentially improving long-term cardiovascular outcomes.

Clinical Best Practices

• Incorporate FH-PeDS or ML-FH-PeDS into pediatric lipid screening protocols to enhance detection accuracy.
• Use these tools to guide decisions on genetic testing, optimizing resource use especially in settings with limited access.
• Educate clinicians on the limitations of adult FH diagnostic criteria when applied to children.
• Ensure informed consent and ethical considerations when performing genetic testing in pediatric populations.

References

• Familial hypercholesterolemia and cardiovascular risk
• Dutch Lipid Clinics Network criteria
• Simon Broome Register diagnostic criteria
• Machine learning in FH diagnosis